300383-08-8

Basic information

• Product Name: 4-METHYL-3-(MORPHOLINE-4-SULFONYL)BENZOIC ACID
• Synonyms: 4-METHYL-3-(MORPHOLIN-4-YLSULFONYL)BENZOIC ACID;4-METHYL-3-(MORPHOLINE-4-SULFONYL)BENZOIC ACID;4-Methyl-3-(4-morpholinylsulfonyl)benzoic acid
• CAS NO: 300383-08-8
• Molecular Formula: C₁₂H₁₅NO₅S
• Molecular Weight: 285.32
• Mol File: 300383-08-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 518.4±60.0 °C(Predicted)
• Appearance: /
• Density: 1.394±0.06 g/cm3(Predicted)
• PKA: 3.98±0.10(Predicted)
• CAS DataBase Reference: 4-METHYL-3-(MORPHOLINE-4-SULFONYL)BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHYL-3-(MORPHOLINE-4-SULFONYL)BENZOIC ACID(300383-08-8)
• EPA Substance Registry System: 4-METHYL-3-(MORPHOLINE-4-SULFONYL)BENZOIC ACID(300383-08-8)

Safety Data

• Hazardous Substances Data: 300383-08-8(Hazardous Substances Data)

Usage

General Description

4-METHYL-3-(MORPHOLINE-4-SULFONYL)BENZOIC ACID is an organic compound with a molecular formula of C14H15NO5S. It is a white to off-white powder that is insoluble in water but soluble in organic solvents. This chemical is commonly used as a building block in the synthesis of pharmaceuticals and other organic compounds. It is also known for its potential use as an inhibitor of certain enzymes and as a potential drug target for the treatment of various diseases. Additionally,

Upstream product

• 110-91-8 morpholine 
• 2548-29-0 3-(chlorosulfonyl)-4-methylbenzoic acid 

Downstream Products

• 418777-91-0 C₁₂H₁₆N₂O₄S 

Relevant articles and documents

ARYLSULFONAMIDE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR

Compounds are provided which bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, the compounds having the general formula (I) and the formula (IA) wherein, R1, R2, R3, R4, R5/sup

Benzimidazol-2-yl or benzimidazol-2-ylthiomethyl benzoylguanidines as novel Na+/H+ exchanger inhibitors, synthesis and protection against ischemic-reperfusion injury

A novel series of benzimidazol-2-yl or benzimidazol-2-ylthiomethyl benzoylguanidines were designed and synthesized as Na+/H+exchanger inhibitors. Most of them were found to inhibit NHE1-mediated platelet swelling in a concentration-dependent manner, and to have significant cardioprotective effect against myocardial ischemic-reperfusion injury, among which compounds 10a and 34 were more potent than cariporide in both in vivo and in vitro tests.